Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus

Autor: Murray B. Urowitz, Cynthia Aranow, Yumi Asukai, Damon L. Bass, Ian N. Bruce, Deven Chauhan, Maria Dall'Era, Richard Furie, Norma Lynn Fox, Jennifer A. Gilbride, Anne Hammer, Ellen M. Ginzler, Tania Gonzalez‐Rivera, Roger A. Levy, Joan T. Merrill, Holly Quasny, David A. Roth, William Stohl, Ronald van Vollenhoven, Daniel J. Wallace, Michelle Petri

Publikováno v: Urowitz, M B, Aranow, C, Asukai, Y, Bass, D L, Bruce, I N, Chauhan, D, Dall'Era, M, Furie, R, Fox, N L, Gilbride, J A, Hammer, A, Ginzler, E M, Gonzalez-Rivera, T, Levy, R A, Merrill, J T, Quasny, H, Roth, D A, Stohl, W, van Vollenhoven, R, Wallace, D J & Petri, M 2022, ' Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus ', Arthritis Care and Research, vol. 74, no. 11, pp. 1822-1828 . https://doi.org/10.1002/acr.24901

Organ damage is a key determinant of poor long-term prognosis and early death in patients with systemic lupus erythematosus (SLE). Prevention of damage is a key treatment goal of the 2019 update of the European Alliance of Associations for Rheumatolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c81a899c9b46ed97a967794594c7bb5
http://www.scopus.com/inward/record.url?scp=85135523522&partnerID=8YFLogxK

Phase III / IV , Randomized, Fifty‐Two –Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Autor: David M. Roth, Susan W Burriss, Michelle Miller, J. Groark, Kathleen Maksimowicz-McKinnon, Luiz Sergio Guedes Barbosa, Amy Pierce, Ellen M. Ginzler, Mittermayer Barreto Santiago, Beulah Ji, Jennifer A Gilbride, Saira Z Sheikh, Richard Furie, Amit Saxena, Jim C. Oates, Damon Bass, David D'Cruz

Publikováno v: Arthritis & Rheumatology. 74:112-123

Objective Enrollment of patients of Black African ancestry with systemic lupus erythematosus (SLE) in Phase 2 and 3 belimumab trials was not reflective of the racial distribution observed in the lupus population. This study assessed efficacy and safe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::50c9fae2800aa2420a308a9eff97554a
https://doi.org/10.1002/art.41900

Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Autor: Ellen, Ginzler, Luiz Sergio, Guedes Barbosa, David, D'Cruz, Richard, Furie, Kathleen, Maksimowicz-McKinnon, James, Oates, Mittermayer Barreto, Santiago, Amit, Saxena, Saira, Sheikh, Damon L, Bass, Susan W, Burriss, Jennifer A, Gilbride, James G, Groark, Michelle, Miller, Amy, Pierce, David A, Roth, Beulah, Ji

Publikováno v: Arthritisrheumatology (Hoboken, N.J.). 74(1)

Enrollment of patients of Black African ancestry with systemic lupus erythematosus (SLE) in phase II and phase III of the belimumab trials was not reflective of the racial distribution observed in the lupus population. This study was undertaken to as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::84e1dc5f0fc4e29954ab82e9ab1f36c8
https://pubmed.ncbi.nlm.nih.gov/34164944